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to compare medical costs in a managed care setting for individu-
als with the following diagnoses: diabetes mellitus (DM), hyper-
tension (HYP), and hypercholesterolemia (HC). In so doing,
this research will allow payers to understand the comparative
resource implications of these common conditions. METHODS:
Data from the i3 LabRx Database were used for this study. Adult
patients who were diagnosed with DM (N = 2,815), HYP
(N = 6,073), or HC (N = 11,442) were included in the study.
Differences among the three groups were examined using chi-
square statistics for categorical variables and t-statistics for con-
tinuous variables. Two-year cost comparisons among the cohorts
were conducted using a multivariate regression that controlled
for patient characteristics, general health status and comorbid
conditions. RESULTS: Compared to the DM cohort, the HYP
cohort was signiﬁcantly older and less likely to be male, while the
HC cohort was more likely to be male. Individuals diagnosed
with HYP or HC had signiﬁcantly lower total direct two-year
medical costs compared to those in the DM cohort (-$4,588,
p < 0.0001; and -$9,062, p < 0.0001 respectively) as well as
signiﬁcantly lower inpatient costs (-$3,640, p < 0.0001;
-$13,463, p < 0.0001), and outpatient prescription drug costs
(-$1,518, p < 0.0001; -$2,823, p < 0.0001). In addition,
patients in the HYP or HC cohorts were found to have signiﬁ-
cantly lower disease-speciﬁc total direct two-year medical costs
(-$1017, p < 0.0001; -$4941, p < 0.0001, respectively) com-
pared to individuals in the DM cohort. CONCLUSION: Results
from this study indicated signiﬁcant differences in demographic
characteristics and comorbidities among individuals diagnosed
with DM, HYP, or HC. These differences translated into signiﬁ-
cant cost differences, with patients diagnosed with DM experi-
encing both higher total medical costs and higher disease-speciﬁc
medical costs than individuals diagnosed with either HYP or HC.
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OBJECTIVES: Thiazolidinediones (TZDs) were ﬁrst introduced
in the late 1990s as adjunctive oral therapy for patients with type
2 diabetes mellitus (T2DM). The comparative economic values
of TZD therapeutic options currently available in the US mar-
ketplace are not well characterized. We estimated the cost-
effectiveness of pioglitazone compared with rosiglitazone in
treating T2DM consistent with AMCP cost-effectiveness guide-
lines. METHODS: Clinical efﬁcacy and baseline parameters were
taken from Goldberg RB et al, 2005, and entered into a previ-
ously validated, Markov-based economic model for T2DM. The
model was used to project long-term improvements in clinical
and economic outcomes comparing pioglitazone with rosiglita-
zone. A series of Markov constructs simulated the progression of
diabetes-related complications (cardiovascular, neuropathy, renal
and eye disease). Transition probabilities and HbA1c-dependent
adjustments were derived from published epidemiological
studies. Costs of T2DM complications were taken from pub-
lished sources. Drug acquisition costs for pioglitazone and
rosiglitazone were assumed to be $4.91/day and $4.18/day,
respectively (WAC prices, 2007), and remained constant. A time
horizon of 35 years was used, with costs and clinical outcomes
discounted at 3% per annum. Univariate sensitivity analyses
were conducted to test robustness of the base case cost-
effectiveness ratio scenarios. RESULTS: The incremental life-
years and quality-adjusted life years gained for pioglitazone
versus rosiglitazone were 0.180 and 0.129 years, respectively, at
an overall increased cost of $3241 per patient over the simulation
period. Therefore, the incremental cost-effectiveness ratios were
$17,981/LY and $25,219/QALY gained, respectively, in our base
case analysis. One-way sensitivity analyses demonstrated that
with variation in key input parameters (discount rates, HbA1c,
lipid effects, etc.); cost-effectiveness ﬁndings were most sensitive
to changes in HbA1c and high density lipoprotein (HDL) effects.
CONCLUSION: Our economic modeling analysis suggests that
pioglitazone delivers superior economic value when compared to
rosiglitazone due to improved clinical outcomes speciﬁcally
related to HDL effects.
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OBJECTIVES: Sitagliptin was the ﬁrst dipeptidyl peptidase 4
(DDP-IV) inhibitor to be approved by the FDA. The com-
parative economic value of thiazolidinediones (TZDs) and the
new (DPP-IV) class of oral diabetes medications has not been
studied. We estimated the cost-effectiveness of pioglitazone
compared with sitagliptin in treating T2DM over a lifetime
horizon in the US setting. METHODS: Clinical efﬁcacy param-
eters for pioglitazone were extracted from Goldberg RB et al,
2005. Sitagliptin parameters were extracted from Aschner P
et al, 2006 and assumed no lipid effects. Both were entered into
a validated economic model for T2DM. A series of Markov
constructs simulated the progression of diabetes-related compli-
cations (cardiovascular, neuropathic, renal, and ophthalmic).
Transition probabilities and HbA1c-dependent adjustments
were derived from published epidemiological studies. Mean
baseline HBA1c was comparable (7.6% for pioglitazone,
8.04% for sitagliptin). Costs of diabetes complications were
taken from published sources. Drug acquisition costs for piogli-
tazone and sitagliptin were assumed to be $4.91/day and $4.86/
day, respectively (WAC prices, 2007), and continued over the
duration of the simulation. The time horizon was 35 years and
costs were discounted at 3% per annum. Univariate sensitivity
analyses were conducted to test the robustness of the base case
cost-effectiveness ratios. RESULTS: The incremental life-years
(LY) and quality-adjusted life years (QALYs) gained for piogli-
tazone versus sitagliptin were 0.111 and 0.075 years, respec-
tively, at an overall increased total health care cost of $359
per patient over the speciﬁed time horizon. Therefore, the
incremental cost-effectiveness ratios (ICER) were $3236/LY
and $4804/QALY gained for pioglitazone versus sitagliptin.
Sensitivity analyses demonstrated that the base case cost-
effectiveness ratios were most sensitive to changes in HbA1c
and high density lipoprotein (HDL) values. CONCLUSION:
Our economic modeling analysis suggests that pioglitazone may
deliver superior economic value when compared to sitagliptin
due to improved HbA1c and cardiovascular outcomes at rea-
sonable incremental cost.
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